Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...
The strains currently circulating are mostly descendants of KP.2, meaning the vaccines should be “a pretty good match,” Shapiro said. With a rapidly evolving virus, it’s never going to be a perfect ...
Moderna's Spikevax COVID vaccine brought in sales of $1.8 billion, up 3.5% over the previous year and handily beating analysts' average expectations of $1.38 billion. The company said it benefited ...